chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Vaccine received at 7:45. First symptoms was sore arm injection site and headache about noon. At 3 in the afternoon, chills, fever 101, and severe fatigue. The morning of the 21 of January fever and chills continued.
Gastritis, severe acid reflux, painful menstruation, prolonged menstrual bleeding and nerve tingling in hands
Lost eyesight in left eye; Leg weakness; have no balance and she cannot walk in a straight line; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 61 year-old female patient received bnt162b2 (BNT162B2), administration date 15Sep2021 (Lot number: FC3182) at the age of 61 years as dose 2, single for covid-19 immunisation. The patient had no relevant medical history. The patient's concomitant medications were not reported. Vaccination history included: Bnt162b2 (Dose 1, Lot Number / Expiry Date: FC3181/unknown, Route, Anatomical Location: right arm), administration date: 25Aug2021, when the patient was 61 years old, for Covid-19 Immunization.  The following information was reported: BLINDNESS (medically significant) with onset 01Oct2021, outcome "not recovered", described as "Lost eyesight in left eye"; LIMB DISCOMFORT (non-serious) with onset Sep2021, outcome "not recovered", described as "Leg weakness"; BALANCE DISORDER (non-serious) with onset Sep2021, outcome "not recovered", described as "have no balance and she cannot walk in a straight line". Patient stated that the events occurred after her second vaccine and she had the booster at a later time. Patient did not require a visit Emergency Room or Physician Office. The patient did not receive any other vaccines within four weeks prior to the vaccination and no AE(s) following prior vaccinations.
shingles; This is a spontaneous report from a contactable nurse (patient). A 89-year-old female patient received second dose of bnt162b2 (COMIRNATY, Formulation: Solution for injection; Batch/Lot number and Expiry date was not reported), via an unspecified route of administration on 24Mar2021 (at the age of 89-years-old) as dose 2, single for COVID-19 immunization. Medical history and concomitant medications were not reported. The patient previously received first dose of bnt162b2 (COMIRNATY, Formulation: Solution for injection; Batch/Lot number and Expiry date was not reported), via an unspecified route of administration on unspecific date as dose 1, single for COVID-19 immunization and also received Flu shot on unspecific date and never had a problem with the Flu shot before. On 02Apr2021, 9 days later after second COVID vaccination, the patient experienced shingles. Patient came down with a really bad case of the shingles. The events resulted in doctor or other healthcare professional office/clinic visit. Patient reports her doctor told her to wait at least a year to see if a booster dose was offered. She was asking whether she have to wait for a year to get the booster dose. Patient wants to know how long should she wait to get the Flu shot. Wants to know how close in between can the Flu shot be given and COVID shot taken and asks is there a time between the second COVID shot and the booster shot because she had shingles. The outcome of the event is unknown.  The lot number for the vaccine, [BNT162B2], was not provided and will be requested during follow up.
Patient developed symptoms consistent with Covd-19 tested positive for Covid on 3/27/21
Patient began vomiting 30 minutes after injection. Stated was clammy and having hot flashes. Then complained of having a headache. At 1400 Patient stated felt no side effects.
Body is swelling and its swollen, I am swell up; Forearms are tight; Swollen elbows; Swollen hands; Skin is really gonna burst; This is a spontaneous report from a contactable consumer or other non hcp (patient). A patient of unspecified age and gender received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, Formulation: solution for injection, Lot Number: EW0170, Expiry date: Unknown) via an unspecified route of administration on 20Apr2021 as dose 1, single for COVID-19 immunization. The patient medical history and concomitant medications were not reported. On unspecified date in 2021, the patient experienced body is swelling and its swollen, i am swell up, forearms are tight, swollen elbows, swollen hands, skin is really gonna burst. The outcome of events was unknown.  No follow-up attempts are needed. No further information is expected.
Cold sweats, chills, red, itchy, swollen arm from injection site down to elbow, weakness in arm, shooting pains down into fingers, fever.
1st dose in 2021, did not get 2nd dose; This case was reported by a pharmacist via call center representative and described the occurrence of incomplete course of vaccination in a patient who received Herpes zoster (Shingrix) for prophylaxis.   Previously administered products included Shingrix (1st dose of Shingrix was administered on 10th May 2021).   On an unknown date, the patient received the 2nd dose of Shingrix. On an unknown date, unknown after receiving Shingrix, the patient experienced incomplete course of vaccination. On an unknown date, the outcome of the incomplete course of vaccination was unknown.   Additional Information: GSK receipt date: 15-SEP-2022 Reporter's comment: The Healthcare Professional(HCP) reported that the patient did not get the 2nd dose. The physician had told to restart the series. No other information available. The reporter did not consent to follow-up. Additional supportive information: Till the time of reporting, the patient did not receive the 2nd dose of Shingrix, which led to incomplete course of vaccination.
This spontaneous report was received from a medical assistant referring to a 59 year old patient. There was no information about the patient's concurrent conditions, concomitant therapies or medical history provided. On 08-JUN-2017, the patient was vaccinated with an improperly stored dose of PNEUMOVAX 23 with lot # N003997 and expiration date 20-OCT-2018 (dose and route of administration were not reported) for prophylaxis. There was no adverse effect or product quality complaint reported. No excursion details had been determined at the time of the report. There was a data logger involved. This is one of several reports received from the same reporter. Sender's Comments: US-009507513-1708USA011654.
Pt broke out in hives within a few minutes of administering vaccines.   Pt was also crying during vaccine administration.  Pt was given benadryl and  prelone.  Hives resolved about 20 mins after prelone - 45 minutes after onset.  No DIB.
Fever 101.5; arm pain; neck / pain; should pain; tiredness; cold; headache; This case was reported by a consumer via call center representative and described the occurrence of fever in a 67-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   Previously administered products included Shingrix (1st dose received on an unknown date, no reaction).   On an unknown date, the patient received the 2nd dose of Shingrix. On an unknown date, less than a day after receiving Shingrix, the patient experienced fever, pain in arm, neck pain, shoulder pain, tiredness, cold and headache. On an unknown date, the outcome of the fever, pain in arm, neck pain, shoulder pain, tiredness, cold and headache were recovered/resolved.   It was unknown if the reporter considered the fever, pain in arm, neck pain, shoulder pain, tiredness, cold and headache to be related to Shingrix.  Additional details were reported as follows: The age at vaccination was not reported. Patient received 2nd dose of Shingrix and within 10 hours, experienced awful reaction included fever 101.5, arm pain, neck pain, shoulder pain, tiredness, cold and headache and all their events got resolved within 24 hours. Patient wondered why there was a reaction to the 2nd dose and not to 1st dose of Shingrix. The reporter did not consented to follow up.
General pain, aching, chills, muscle pain, joint pain, muscles in forearms when lifting arms hurt.
ActHIB was reconstituted with sterile water and not with the diluent supplied in the box, no AE; Initial information received on 29-Jan-2020 regarding an unsolicited valid non-serious case received from a nurse.  This case involves patient (may be a toddler) who received HIB (PRP/T) VACCINE [ACT-HIB] (lot number not reported) via unknown route in unknown administration site for prophylactic vaccination on an unknown date.  Medical history, past medical treatment, vaccination and family history were not provided.  It was an actual medication error case due to wrong solution used in drug reconstitution.  It was reported that the ActHIB was reconstituted with sterile water and not with the diluent supplied in the box.  At the time of report, no adverse event was reported.  This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holders compliance with the requirements set out in Directive and Module VI of the Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.  Information on the batch number was requested.
itching on face both cheeks, whelps both cheeks, fine rash;given DPH that noc then Thursday AM & PM;also APAP pain reliever;
Little bit of a fever; Weak a little bit; Felt woozy; This spontaneous case was reported by a consumer and describes the occurrence of ASTHENIA (Weak a little bit), PYREXIA (Little bit of a fever) and DIZZINESS (Felt woozy) in an 80-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 010MZ0A) for COVID-19 vaccination.  The patient's past medical history included Diabetes since an unknown date, Blood pressure since an unknown date and Prostate ablation since an unknown date. Concomitant products included ACETYLSALICYLIC ACID (ASPIRIN (E.C.)) for an unknown indication.   On 13-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 10-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 10-Feb-2021, the patient experienced ASTHENIA (Weak a little bit), PYREXIA (Little bit of a fever) and DIZZINESS (Felt woozy). On 11-Feb-2021, ASTHENIA (Weak a little bit), PYREXIA (Little bit of a fever) and DIZZINESS (Felt woozy) had resolved.            Treatment information includes patient did not take any treatment for fever.
The next morning, I  looked flushed and short of breath and had a temp pain was severe in my arm and all over. couldn't eat. Last night i was able to eat a little but it was hard to get down. i wasnt tasting things right.  called Dr said to take a couple of Tylenol and to call vaers for advice. Was very weak.
patient was given an undiluted dose; patient was given an undiluted dose; patient was given an undiluted dose; She is having the chest pain; fever; This is a spontaneous report received from a contactable reporter(s) (Pharmacist) from medical information team for a Pfizer sponsored program.  A 10 year-old male patient received bnt162b2 (BNT162B2), administered in arm left, administration date 20Jan2022 (Lot number: FL8094) at the age of 10 years as dose 2, single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: Covid-19 vaccine (DOSE 1, MANUFACTURER UNKNOWN), for Covid-19 immunization.  The following information was reported: POOR QUALITY PRODUCT ADMINISTERED (non-serious), PRODUCT PREPARATION ERROR (non-serious), OVERDOSE (non-serious) all with onset 20Jan2022, outcome "unknown" and all described as "patient was given an undiluted dose"; CHEST PAIN (non-serious) with onset Jan2022, outcome "unknown", described as "She is having the chest pain"; PYREXIA (non-serious) with onset Jan2022, outcome "unknown", described as "fever".  Additional information: Patient was given an undiluted dose of the Pfizer-Biontech Covid19 vaccine for pediatrics (orange cap). Caller stated that patient has been experiencing fever since then.  No follow-up attempts are possible. No further information is expected.
3/24 - felt slight swelling in throat but subsided; 3/25 - sore arm for4 days; fever above 101 on 3/25; neck ache and head ache on 3/25; tired on 3/25
Annoying armpit pain, still have 3 days later. Very strong  pain at shoulder blade area going all the way to the front. It feels like something is wrong with my lungs and my spine. Pain is  much worse when inhaling. Sometimes makes me cough. I had back pain after the 1st shot, and was finally getting better. Now it is back in full force but only between shoulder blades. Constant pain, sometimes get worse, sometimes better but never goes away.  Neck pain, and hard to move neck; now getting better. I had first shot in left arm and second in right arm. After 2nd shot my Left arm (the one that got 1st shot) started being sore and i was not feeling anything in  the right arm  Where i got the shot. Then it finally switched with the added "bonus" of the armpit pain.  I was very very tired fist day but then could not sleep for the next two nights Due to back pain and general discomfort. After 2 nights of no sleep i was really beaten up , with a minor headache all day ,maybe because of vaccine but also because of lack of sleep. No fever, when i checked  37.3 A bit of chills night 2
From initial information received on 13Aug04 from a RN regarding an adverse event occurring, it was reported that a 25 year old female pt received a second dose of Menomune A/C/Y/W-135, lot number UE301AA, administered SC in the left upper arm on 13Aug04 at 9:20AM. 160 minutes later, at 12:00PM, the pt experienced stiffness to the back of her neck. The pt recovered from this event. From additional information received on 12Oct04 from the reporting facility, it was reported that the pt was monitored by the company physician. On presentation, she no longer had symptoms and was released back to work full duty. On initial presentation, the pt was treated with an over the counter dose of ibuprofen and returned back to work. Her symptoms lasted a few hours. No further information is anticipated, this case is considered closed.
Information has been received from a physician concerning a 14 year old female who on 02-OCT-2007 was vaccinated with her first dose of Gardasil (lot #657621/0387U) injection.  Concomitant therapy included MENACTRA.  On 02-OCT-2007, after receiving the vaccine, the patient fainted.  Subsequently, the patient recovered from fainting.  She sought unspecified medical attention.  The office is not sure whether or not the patient will received the second dose.  Additional information has been requested.
Information has been received from a nurse referring to unspecified number of patients of unknown age and gender. During the time period of 30-OCT-2015 through 04-NOV-2015, the patients were vaccinated with improperly stored RECOMBIVAX HB (lot # L014419, expiration date 15-APR-2017) (dose and route were not reported). No symptoms were reported. This is one of several reports received from the same reporter. Additional information has been requested.
Very sick; Horrible rash all over; Took one dose of Vivotif and stopped taking remaining doses; A spontaneous report was received from a nurse on 11AUG2022. It described a male patient (unknown age) who was "very sick" (PT: Illness) and developed a "horrible rash all over" (PT: Rash) following the administration of Vivotif (typhoid vaccine live oral Ty21A) (lot number: unknown) for immunization. Reportedly, the patient "took one dose of Vivotif and stopped taking remaining doses" (PT: Incomplete course of vaccination). It was reported that the patient took only one dose of Vivotif and felt very sick and had a horrible rash all over. Reportedly, the rash was so bad that his doctor recommended him to take oral steroids for the next three weeks. Additionally, it was confirmed that the patient was not going to take any more doses of Vivotif. Furthermore, it was stated that the patient never had any reaction to the typhoid vaccine. The outcome of the reported events was unknown.  Action taken with Vivotif with respect to the events "very sick" and "horrible rash all over" was vaccine withdrawn and for the event "took one dose of Vivotif and stopped taking remaining doses" it was not applicable.  No additional information was reported.  Company comment: A patient became very sick (illness) and developed a horrible rash all over (rash) following the administration of first dose of Vivotif. The patient took one dose of Vivotif and stopped taking remaining doses (incomplete course of vaccination). Further information regarding the events is limited. Considering a temporal association, the causality of illness and rash is assessed as possible with Vivotif. The causality of incomplete course of vaccination is assessed as not applicable with Vivotif. The case is considered non-serious as per medical assessment.; Sender's Comments: A patient became very sick (illness) and developed a horrible rash all over (rash) following the administration of first dose of Vivotif. The patient took one dose of Vivotif and stopped taking remaining doses (incomplete course of vaccination). Further information regarding the events is limited. Considering a temporal association, the causality of illness and rash is assessed as possible with Vivotif. The causality of incomplete course of vaccination is assessed as not applicable with Vivotif. The case is considered non-serious as per medical assessment.
Pt. had a mild allergic reaction as well as a vasovagal reaction. Pt. started to experience the following symptoms: Tingling in the mouth, lightheaded, redness to the face, tingling sensation throughout the body, and difficulty swallowing. given 20mL (50mg) of Benadryl orally in 1759. First set of vitals were taken in 1803 and were the following: BP - 128/74, HR - 77, RR - 21, and SpO2 - 96% on RA. Pt. stated she felt better and was cleared to go home at 1811. Pt. given advice on secondary reactions.
Rash at injection site, began about a week after the injection. Rash is on upper left arm, about 4 inches high and 2 inches wide, red and slightly raised. It may have been present earlier, but wasn't noticed until it began itching on the evening of April 1, 2021. It was itchy/stingy in direct sunlight for one to two days. It is improving today, April 5, 2021. It does not seem serious (and a brief internet search seems to indicate this is relatively common in my demographic), and will not inhibit my second dosage, I just wanted to report for the sake of data collection.
Sore muscle in neck, extreme muscle pain in both legs, nausea, headache, fever, dizzy, unable to concentrate, taste obstructed and extreme tiredness
Redness and chills for 48 hours.  Then February 14 redness 4X5 inches at injection site
11:10am  pt received 1yr vaccines ( Havrix, MMR, Varivax)  pt left the exam room with Gma to get labs , noted that bil thighs , arms and face were bright red and pt was crying, ask to come back in exam room for assessment by Dr. STAT order for 1tsp Benadryl give P.O. @ 11:20am Gm reports pt does get red and blotchy when he gets upset, pt able to drink milk from a bottle and calm down, Gm was ask to stay in exam room for further monitoring before leaving ,   11:35am pt reassessed  pt calm and redness much improved and faded
Have been super sick since the vaccine.  At the shot where administered I have a bright red circle the size of a quarter.  Very hot to the touch.  Will not go away even after day 10.
Patient is <50 years old and not immunocompromised, therefore this 4th total dose (2nd booster) was inadvertently administered, as patient is technically ineligible per EUA. He had a sore arm the day following vaccination.
Swollen, red, hot and tender hand-sized area around injection site, started 1-2 hours after shot.
WEIGHT GAIN; STIFFNESS; JOINT PAIN IN KNEES; First dose administered on 02-jan-2021, Second dose administered on 01-Mar-2021; This spontaneous case was reported by a consumer and describes the occurrence of WEIGHT INCREASED (WEIGHT GAIN), MUSCULOSKELETAL STIFFNESS (STIFFNESS), ARTHRALGIA (JOINT PAIN IN KNEES) and INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (First dose administered on 02-jan-2021, Second dose administered on 01-Mar-2021) in a 65-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.    Co-suspect product included non-company product UPADACITINIB (RINVOQ) for Rheumatoid arthritis.    No Medical History information was reported.   On 02-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 01-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 02-May-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient started UPADACITINIB (RINVOQ) (Oral) at an unspecified dose. On an unknown date, UPADACITINIB (RINVOQ) (Oral) dosage was changed to at an unspecified dose. On 01-Mar-2021,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (First dose administered on 02-jan-2021, Second dose administered on 01-Mar-2021). On an unknown date, the patient experienced WEIGHT INCREASED (WEIGHT GAIN), MUSCULOSKELETAL STIFFNESS (STIFFNESS) and ARTHRALGIA (JOINT PAIN IN KNEES). At the time of the report, WEIGHT INCREASED (WEIGHT GAIN) had not resolved and MUSCULOSKELETAL STIFFNESS (STIFFNESS), ARTHRALGIA (JOINT PAIN IN KNEES) and INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (First dose administered on 02-jan-2021, Second dose administered on 01-Mar-2021) outcome was unknown. Not Provided    DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Weight: 45 lbs and Gain.         It was unknown if patient was enrolled in a COVID-19 Vaccine Trial.  No concomitant product use was reported.   Patient was administered with booster dose on 02-MAY-2021.  All three doses of moderna vaccine taken one in once.  Patient gained significant amount of weight during their time on therapy 45 lbs.  No treatment information was provided.  The reporter causality for the event of weight gain with RINVOQ (UPADACITINIB) was a reasonable possibility. The reporter causality for the events stiffness and joint pain in knees with RINVOQ (UPADACITINIB) was not provided.
This spontaneous report as received from a medical assistant refers to a patient of unknown age and gender. On 16-JUL-2014 the patient was vaccinated inadvertently with an improperly stored (Oka/Merck) VARIVAX, subcutaneous, 0.5 ml (lot number and expiration date not reported). No adverse effects reported. This is one of two reports from the same reporter (1407USA008036). Additional information has been requested.
She had chest pain in her middle chest and to the left of middle. At first the pain was moving, it was up higher and down to ribs and is not upper chest, center chest and left of center of chest. hurts when breathing. She went to ER hour and half after pain started and then her leg, upper thigh, started hurting. elevating her leg helped the leg pain. The leg pain has gotten better. She also had a bad headache the first night and the night after the vaccine but the headaches have gotten better since.